Hemostasis in patients with normal and impaired renal function under treatment with cefodizime.
Ten patients (two with normal, eight with impaired renal function) on their usual diet were treated with cefodizime (HR 221) for seven days. The dosage was 4 g/day, adapted to renal function as appropriate. Platelet function, plasma coagulation and vitamin K metabolism were investigated before and on day 7 of therapy. Platelet function and plasma coagulation remained unchanged, regardless of the size of the serum antibiotic trough levels, in both normal and impaired renal function. Vitamin K1 metabolism remained unaffected, since no increase in vitamin K1 2,3 epoxide in the circulation was observed during the therapy. Cefodizime (HR 221), a parenteral aminothiazole cephalosporin, does not affect hemostasis.
Department of Internal Medicine, University of Heidelberg.
K
K
Andrassy
J
J
Koderisch
D
D
Trenk
E
E
Jähnchen
A
A
Iwand
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D014812:Vitamin K / Q000378:metabolism
D014812:Vitamin K; D002439:Cefotaxime; C033356:cefodizime